论文部分内容阅读
目的探讨紫杉醇静脉化疗联合顺铂、甘露聚糖肽胸腔灌注治疗晚期非小细胞肺癌(NSCLC)合并胸腔积液的疗效及安全性。方法 62例晚期NSCLC合并胸腔积液患者,引流干净胸腔积液后胸腔内灌注顺铂和甘露聚糖肽,第2天予以紫杉醇静脉化疗,2个疗程后观察疗效及毒性。结果 62例患者,PR 49例,NC 9例,PD 4例,总有效率为79.0%。不良反应以Ⅰ、Ⅱ级为主。结论紫杉醇静脉化疗联合顺铂、甘露聚糖肽胸腔灌注治疗晚期NSCLC合并胸腔积液安全有效。
Objective To investigate the curative effect and safety of paclitaxel intravenous chemotherapy combined with cisplatin and mannan peptide thoracic perfusion in the treatment of advanced non-small cell lung cancer (NSCLC) combined with pleural effusion. Methods Sixty-two patients with advanced NSCLC complicated with pleural effusion were treated with pleural effusion of cisplatin and mannan peptide after drainage of pleural effusion. Intravenous chemotherapy with paclitaxel was given on the second day. The curative effect and toxicity were observed after two courses. Results 62 patients, PR 49 cases, NC 9 cases, PD 4 cases, the total effective rate was 79.0%. Adverse reactions to Ⅰ, Ⅱ-based. Conclusion Paclitaxel intravenous chemotherapy combined with cisplatin and mannan peptide thoracic perfusion in the treatment of advanced NSCLC combined with pleural effusion is safe and effective.